Who are Urinary Kallikrein's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/urinary-kallikrein.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Urinary Kallikrein — Competitive Intelligence Brief

Urinary Kallikrein (Urinary Kallikrein) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Serine protease / Kinin-kallikrein system activator. Area: Cardiovascular.

marketed Serine protease / Kinin-kallikrein system activator Kininogen (substrate); B1 and B2 bradykinin receptors (downstream) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Urinary Kallikrein (Urinary Kallikrein) — Second Affiliated Hospital, School of Medicine, Zhejiang University. Urinary kallikrein is a serine protease that cleaves kininogen to release bradykinin, a potent vasodilator and natriuretic peptide that lowers blood pressure and improves renal perfusion.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Urinary Kallikrein TARGET	Urinary Kallikrein	Second Affiliated Hospital, School of Medicine, Zhejiang University	marketed	Serine protease / Kinin-kallikrein system activator	Kininogen (substrate); B1 and B2 bradykinin receptors (downstream)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Serine protease / Kinin-kallikrein system activator class)

Second Affiliated Hospital, School of Medicine, Zhejiang University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Urinary Kallikrein — Competitive Intelligence Brief. https://druglandscape.com/ci/urinary-kallikrein. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab